Alex Anstey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alex Anstey has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
R J Hift
Lennox Eales Porphyria Laboratories, MRC/UCT Liver Research Centre and Department of Medicine, University of Cape Town and Groote Schuur Hospital , South Africa
2 shared publicationsA.D. Pearse
Department of Dermatology, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, U.K. *Department of Dermatology, Royal Liverpool University Hospital, Liverpool L7 8XP, U.K.†Dermatology Centre, University of Manchester, Hope Hospital, Salford M6 8HD, U.K.
1 shared publicationKnud Kragballe
From the Royal Gwent Hospital, Newport, Wales, UK, and Marselisborg Center, Aarhus University Hospital, Århus C, Denmark
1 shared publication- Lesley Elizabeth Rhodes
Centre for Dermatology Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, NIHR Manchester Biomedical Research Centre, The University of Manchester, Manchester, UK
1 shared publication - Nicholas J. Reynolds
Institute of Translational and Clinical Medicine, Newcastle University and NIHR Biomedical Research Centre , Newcastle upon Tyne
1 shared publication P.E. Bowden
Department of Dermatology, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, U.K. *Department of Dermatology, Royal Liverpool University Hospital, Liverpool L7 8XP, U.K.†Dermatology Centre, University of Manchester, Hope Hospital, Salford M6 8HD, U.K.
1 shared publication
Latest Publications
- 10 October 2013
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 169 (4) , 729-730
Reading theBritish Journal of Dermatology
- 10 October 2013
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 169 (4) , 729-730
Reading theBritish Journal of Dermatology
- 13 August 2013
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 169 (2) , 238
TheBritish Journal of Dermatology: 125 years, 28 editors, enduring values
- 13 August 2013
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 169 (2) , 238
TheBritish Journal of Dermatology: 125 years, 28 editors, enduring values
- 26 October 2010
- Published by Wiley in British Journal of Dermatology
- Vol. 163 (5) , 901-902
A paradigm for phototherapy clinical-genetic research
- 26 October 2010
- Published by Wiley in British Journal of Dermatology
- Vol. 163 (5) , 901-902
A paradigm for phototherapy clinical-genetic research
- 24 June 2010
- Published by Wiley in British Journal of Dermatology
- Vol. 163 (1) , 232-233
Book Review
- 13 January 2010
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 162 (2) , 237-238
Fumaric acid esters in the treatment of psoriasis - commentary on ‘Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study’ by Wain et al.
- 13 January 2010
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 162 (2) , 237-238
Fumaric acid esters in the treatment of psoriasis - commentary on ‘Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study’ by Wain et al.
- 1 August 2009
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 161 (2) , 219-220
Management of atopic dermatitis: nonadherence to topical therapies in treatment of skin disease and the use of calcineurin inhibitors in difficult eczema
- 1 August 2009
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 161 (2) , 219-220
Management of atopic dermatitis: nonadherence to topical therapies in treatment of skin disease and the use of calcineurin inhibitors in difficult eczema
- 1 July 2009
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 161 (1) , 216-217
Book Review
- 1 July 2009
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 161 (1) , 216-217
Book Review
- 1 June 2009
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 160 (6) , 1139
‘Real decisions’ on psoriasis care from informed clinicians
- 1 June 2009
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 160 (6) , 1139
‘Real decisions’ on psoriasis care from informed clinicians
- 1 December 2007
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 83 (986) , 739-748
Liver disease in erythropoietic protoporphyria: insights and implications for management
EPP is an inborn error of haem biosynthesis caused by mutations in the gene encoding the mitochondrial enzyme ferrochelatase (FECH), the final enzyme in the haem biosynthetic pathway (fig 1).1–5 It was first described by Magnus et al in 1962.6 Ferrochelatase catalyses the insertion of ferrous iron into protoporphyrin to form haem, and when defective or deficient, accumulation of protoporphyrin ensues. Ferrochelatase is active in cells that produce haem including erythroid precursors in the bone marrow7 and hepatocytes.8 However, the majority of protoporphyrin (80% or more) originates from bone marrow with most of the remainder generated by the liver (fig 2).7 9
- 1 December 2007
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 83 (986) , 739-748
Liver disease in erythropoietic protoporphyria: insights and implications for management
EPP is an inborn error of haem biosynthesis caused by mutations in the gene encoding the mitochondrial enzyme ferrochelatase (FECH), the final enzyme in the haem biosynthetic pathway (fig 1).1–5 It was first described by Magnus et al in 1962.6 Ferrochelatase catalyses the insertion of ferrous iron into protoporphyrin to form haem, and when defective or deficient, accumulation of protoporphyrin ensues. Ferrochelatase is active in cells that produce haem including erythroid precursors in the bone marrow7 and hepatocytes.8 However, the majority of protoporphyrin (80% or more) originates from bone marrow with most of the remainder generated by the liver (fig 2).7 9
- 14 March 2007
- Vol. 56 (7) , 1009-18
Liver disease in erythropoietic protoporphyria: insights and implications for management.
- 14 March 2007
- Vol. 56 (7) , 1009-18
Liver disease in erythropoietic protoporphyria: insights and implications for management.